Upadacitinib

Advances in clinical management of acute severe ulcerative colitis

Journal: Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences

Published: April 13, 2026

Topical calcineurin inhibitors for atopic dermatitis are not associated with the development of subsequent lymphoma: A pharmacovigilance study using the FAERS database (2014-2025).

Journal: JAAD international

Published: April 13, 2026

Self-severing circuits facilitate passage of ingestible electronic sensor-guided therapeutics.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

The use of upadacitinib for refractory pityriasis rubra pilaris: A case report.

Journal: JAAD case reports

Published: April 09, 2026

Treatment of Giant cell arteritis: focus on upadacitinib.

Journal: Expert opinion on pharmacotherapy

Published: April 02, 2026

Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis: a network meta-analysis of phase 3-4 randomized trials.

Journal: The Journal of dermatological treatment

Published: April 01, 2026

A case report of Crohn's disease in a child treated with upadacitinib

Journal: Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics

Published: March 31, 2026

Engineered Protein Nanoparticles Enable Targeted Topical Delivery of Upadacitinib for Enhanced Arthritis Therapy.

Journal: ACS applied bio materials

Published: March 23, 2026

Janus Kinase Inhibitor Upadacitinib in Elderly-Onset Rheumatoid Arthritis With Hip Osteoarthritis: A Case Report.

Journal: The American journal of case reports

Published: March 21, 2026

Xanthogranuloma disseminatum: Successfully treated with statins followed by upadacitinib.

Journal: JAAD case reports

Published: March 20, 2026

Discovery of YYSW001: A Highly Selective, Orally Bioavailable JAK1 Inhibitor Achieving Efficacy under a Moderate-Inhibition Strategy with Improved Preclinical Tolerability.

Advances in clinical management of acute severe ulcerative colitis

Advances in clinical management of acute severe ulcerative colitis

Topical calcineurin inhibitors for atopic dermatitis are not associated with the development of subsequent lymphoma: A pharmacovigilance study using the FAERS database (2014-2025).

Topical calcineurin inhibitors for atopic dermatitis are not associated with the development of subsequent lymphoma: A pharmacovigilance study using the FAERS database (2014-2025).

Self-severing circuits facilitate passage of ingestible electronic sensor-guided therapeutics.

Self-severing circuits facilitate passage of ingestible electronic sensor-guided therapeutics.

The use of upadacitinib for refractory pityriasis rubra pilaris: A case report.

The use of upadacitinib for refractory pityriasis rubra pilaris: A case report.

Treatment of Giant cell arteritis: focus on upadacitinib.

Treatment of Giant cell arteritis: focus on upadacitinib.

Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis: a network meta-analysis of phase 3-4 randomized trials.

Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis: a network meta-analysis of phase 3-4 randomized trials.

A case report of Crohn's disease in a child treated with upadacitinib

A case report of Crohn's disease in a child treated with upadacitinib

Engineered Protein Nanoparticles Enable Targeted Topical Delivery of Upadacitinib for Enhanced Arthritis Therapy.

Engineered Protein Nanoparticles Enable Targeted Topical Delivery of Upadacitinib for Enhanced Arthritis Therapy.

Janus Kinase Inhibitor Upadacitinib in Elderly-Onset Rheumatoid Arthritis With Hip Osteoarthritis: A Case Report.

Janus Kinase Inhibitor Upadacitinib in Elderly-Onset Rheumatoid Arthritis With Hip Osteoarthritis: A Case Report.

Xanthogranuloma disseminatum: Successfully treated with statins followed by upadacitinib.

Xanthogranuloma disseminatum: Successfully treated with statins followed by upadacitinib.

Discovery of YYSW001: A Highly Selective, Orally Bioavailable JAK1 Inhibitor Achieving Efficacy under a Moderate-Inhibition Strategy with Improved Preclinical Tolerability.

Discovery of YYSW001: A Highly Selective, Orally Bioavailable JAK1 Inhibitor Achieving Efficacy under a Moderate-Inhibition Strategy with Improved Preclinical Tolerability.

Upadacitinib for the treatment of geographic tongue: A case report.

Upadacitinib for the treatment of geographic tongue: A case report.